Browse hierarchy: [Ear, Nose, Throat (EN)](/submissions/EN) → [Subpart E — Surgical Devices](/submissions/EN/subpart-e%E2%80%94surgical-devices) → [21 CFR 874.4180](/submissions/EN/subpart-e%E2%80%94surgical-devices/874.4180) → PNZ — Eustachian Tube Balloon Dilation Device # PNZ · Eustachian Tube Balloon Dilation Device _Ear, Nose, Throat · 21 CFR 874.4180 · Class 2_ **Canonical URL:** https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ ## Overview - **Product Code:** PNZ - **Device Name:** Eustachian Tube Balloon Dilation Device - **Regulation:** [21 CFR 874.4180](/submissions/EN/subpart-e%E2%80%94surgical-devices/874.4180) - **Device Class:** 2 - **Review Panel:** [Ear, Nose, Throat](/submissions/EN) ## Identification A Eustachian tube balloon dilation system is a prescription device that includes a flexible catheter attached to an inflatable balloon. The system is intended for use in dilating the cartilaginous portion of the Eustachian tube for treating persistent Eustachian tube dysfunction. ## Classification Rationale Class II (special controls). The special controls for this device are: ## Special Controls *Classification.* Class II (special controls). The special controls for this device are:(1) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be evaluated: (i) Mechanical testing, including tensile and flexural testing of catheter joints and materials. (ii) Durability testing, including fatigue and burst pressure testing of the balloon materials and components. (iii) Inflation and deflation characterization testing, including time and pressure measurements, and leak testing of the balloon. (iv) Verification testing of safety features built into the device must be performed, including the characterization of catheter geometries and distal tip insertion limitation mechanisms. (2) Simulated use testing in a clinically relevant model must demonstrate the reliability of the device to remain mechanically functional throughout the anticipated conditions of use, and validate that the design features limit access to only the cartilaginous portion of the Eustachian tube. (3) The patient-contacting components of the device must be demonstrated to be biocompatible. (4) Performance data must demonstrate the sterility of the device. (5) Performance data must support shelf life by demonstrating continued sterility of the device, package integrity, and device functionality over the identified shelf life. (6) Training must include simulated use on cadavers to ensure users can follow the instructions for use to allow safe use of the device. (7) Labeling must include: (i) Detailed instructions for use. (ii) A detailed summary of the device technical parameters, including maximum allowed inflation pressure, allowable catheter geometries, and available balloon sizes. (iii) A shelf life. In combination with the general controls of the FD&C Act, the Acclarent Aera™ Eustachian Tube Balloon Dilation System is subject to the following special controls: - 1. Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be evaluated: - a. Mechanical testing, including tensile and flexural testing of catheter joints and materials. - b. Durability testing, including fatigue and burst pressure testing of the balloon materials and components. - Inflation and deflation characterization testing, including time and pressure C. measurements, and leak testing of the balloon. - d. Verification testing of safety features built into the device must be performed. including the characterization of catheter geometries and distal tip insertion limitation mechanisms. - 2. Simulated use testing in a clinically relevant model must demonstrate the reliability of the device to remain mechanically functional throughout the anticipated conditions of use, and validate that the design features limit access to only the cartilaginous portion of the Eustachian tube. - 3. The patient-contacting components of the device must be demonstrated to be biocompatible. - 4. Performance data must demonstrate the sterility of the device. - 5. Performance data must support shelf life by demonstrating continued sterility of the device, package integrity and device functionality over the identified shelf life. - 6. Training must include simulated use on cadavers to ensure users can follow the instructions for use to allow safe use of the device. - 7. Labeling must include: - a. Detailed instructions for use. - b. A detailed summary of the device technical parameters, including maximum allowed inflation pressure, allowable catheter geometries, and available balloon sizes. - c. A shelf life. ## Recent Cleared Devices (9 of 9) | Record | Device Name | Applicant | Decision Date | Decision | | --- | --- | --- | --- | --- | | [K253612](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/K253612.md) | Acclarent AERA Eustachian Tube Balloon Dilation System | Acclarent, Inc. | Feb 19, 2026 | SESE | | [K230742](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/K230742.md) | ACCLARENT AERA Eustachian Tube Dilation System | Acclarent, Inc. | Dec 13, 2023 | SESE | | [K223542](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/K223542.md) | TubaVent Balloon Dilatation System | Spiggle & Theis Medizintechnik GmbH | Aug 3, 2023 | SESE | | [K230065](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/K230065.md) | VenSure™ Balloon Dilation System, VenSure™ Light Balloon Dilation System, VenSure™ Nav Balloon Dilation System, VenSure™ ET Balloon Dilation System | Fiagon GmbH | May 26, 2023 | SESE | | [K220027](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/K220027.md) | Audion ET dilation system | Entellus Medical, Inc. | Apr 12, 2022 | SESE | | [K210841](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/K210841.md) | NuVent Eustachian Tube Dilation Balloon | Medtronic Xomed, Inc. | Aug 16, 2021 | SESE | | [K171761](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/K171761.md) | ACCLARENT AERA Eustachian Tube Balloon Dilation System | Acclarent, Inc. | Jan 16, 2018 | SESE | | [K163509](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/K163509.md) | XprESS ENT Dilation System | Entellus Medical, Inc. | Apr 5, 2017 | SESE | | [DEN150056](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ/DEN150056.md) | Acclarent Aera Eustachian Tube Balloon Dilation System | Acclarent, Inc. | Sep 16, 2016 | DENG | ## Top Applicants - Acclarent, Inc. — 4 clearances - Entellus Medical, Inc. — 2 clearances - Spiggle & Theis Medizintechnik GmbH — 1 clearance - Medtronic Xomed, Inc. — 1 clearance - Fiagon GmbH — 1 clearance --- **Source:** [https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ](https://fda.innolitics.com/submissions/EN/subpart-e%E2%80%94surgical-devices/PNZ) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com